757975-90-9

Upstream product

• 290817-22-0 N-(morpholin-4-ylcarbonyl)-L-leucine benzyl ester 
• 51388-20-6 4-benzyloxyaniline hydrochloride 
• 1738-77-8 L-leucine benzyl ester p-toluenesulfonate 
• 15159-40-7 4-morpholinocarbonyl chloride 
• 882296-91-5 (1-{[(4-benzyloxy-phenyl)-(2-nitro-benzenesulfonyl)-amino]-methyl}-propyl)-carbamic acid tert-butyl ester 
• 313067-82-2 N-[4-(benzyloxy)phenyl]-2-nitrobenzenesulfonamide 
• 757976-46-8 tert-butyl [(1S)-1-({[4-(benzyloxy)phenyl]amino}methyl)propyl]carbamate 
• 129739-09-9 4-methyl-2S-[(morpholine-4-carbonyl)amino]pentanoic acid 

Downstream Products

• 757976-49-1 N-((1S)-1-{[(4-hydroxyphenyl)amino]methyl}propyl)-N²-[(morpholin-4-yl)carbonyl]-L-leucinamide 
• 757975-92-1 tert-butyl {4-[((2S)-2-{[N-(morpholin-4-ylcarbonyl)-L-leucyl]amino}butyl)amino]phenoxy}acetate 

Relevant academic research and scientific papers

Arylamine based cathepsin K inhibitors: Investigating P3 heterocyclic substituents

A modification of novel cathepsin K inhibitors I was carried out. The structural design was aimed at reducing the lipophilic character of compounds I for obtaining better pharmacokinetic profiles. This modification afforded several less lipophilic compoun